LFMD LIFEMD INC

LifeMD to Participate in Upcoming Investor Conferences and Panel Discussions

LifeMD to Participate in Upcoming Investor Conferences and Panel Discussions

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in two upcoming investor conferences and a panel discussion.

  • Cantor Fitzgerald GLP-1 Panel: Payor vs. Provider Perspective, November 13, 2023. Justin Schreiber, Chief Executive Officer of LifeMD, will participate in a panel discussion with Andrew Baskin, M.D., Independent Consultant and formerly the Vice President, National Medical Director at Aetna, Inc. regarding their perspectives on GLP-1s.

  • BTIG Digital Health Forum, November 21, 2023. Mr. Schreiber will participate in a panel discussion titled “Using the Platform Approach” at 12:00 p.m. Eastern time and will be available for one-on-one virtual meetings.

  • Sidoti’s Small-Cap Virtual Conference, December 6-7, 2023. Management will be presenting a corporate overview and will be hosting one-on-one meetings with investors. To register for the conference, visit . Registration is free and investors are not required to be a Sidoti client.

About LifeMD, Inc.

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit .

Company Contact

LifeMD, Inc.

Marc Benathen, CFO

Media Contact



EN
10/11/2023

Underlying

LFMDLIFEMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9 NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archiv...

February 23, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Announces Closing of $50 Million Revolving Credit Facility with...

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A. NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was dra...

January 6, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealt...

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end teleh...

January 5, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Pr...

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provide...

December 26, 2025 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIM...

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026 NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME’s America’s Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD’s continued revenue growth, financial stability, and emerging leadership position in the health technology sector. “Inclusion on these lists of North America...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch